JNJ-6892 / J&J, Epirus, Genefar - LARVOL DELTA

Discovery of therapeutic human monoclonal antibody combinations using microfluidics and molecular genomics (AACR 2018) - "...We recently embarked on a discovery campaign for 17 immuno-oncology targets, including PD-1, CTLA-4, GITR, and OX40...Candidates that are high affinity, bind cell surface antigen, and induce immune cell activation are now being tested in combinations for in vitro and in vivo efficacy. Combinations that have significantly better in vitro and in vivo efficacy than benchmark checkpoint inhibitors currently on the market will be moved forward into clinical studies."

Bladder Cancer • Lung Cancer • Melanoma

Positron emission tomography imaging of activated T cells by targeting OX40 reveals spatiotemporal immune dynamics and predicts response to in situ tumor vaccination (AACR 2018) - "OX40 ImmunoPET provides a readily translatable approach for monitoring activated T cells with high sensitivity and specificity. In this instance, integration of molecular imaging and computational immunology enabled systems-level interrogation of vaccine response."

IO Biomarker • Lymphoma